These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 14506193

  • 1. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation.
    Orjuela M, Gross TG, Cheung YK, Alobeid B, Morris E, Cairo MS.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3945S-52S. PubMed ID: 14506193
    [Abstract] [Full Text] [Related]

  • 2. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
    Gross TG, Bucuvalas JC, Park JR, Greiner TC, Hinrich SH, Kaufman SS, Langnas AN, McDonald RA, Ryckman FC, Shaw BW, Sudan DL, Lynch JC.
    J Clin Oncol; 2005 Sep 20; 23(27):6481-8. PubMed ID: 16170157
    [Abstract] [Full Text] [Related]

  • 3. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R, Riess H, Babel N, Hummel M, Lehmkuhl H, Jonas S, Anagnostopoulos I, Papp-Vary M, Reinke P, Hetzer R, Dörken B, Oertel S.
    Transplantation; 2007 Apr 15; 83(7):912-8. PubMed ID: 17460562
    [Abstract] [Full Text] [Related]

  • 4. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.
    González-Barca E, Domingo-Domenech E, Capote FJ, Gómez-Codina J, Salar A, Bailen A, Ribera JM, López A, Briones J, Muñoz A, Encuentra M, de Sevilla AF, GEL/TAMO (Grupo Español de Linfomas), GELCAB (Grupo para el Estudio de los Linfomas Catalano-Balear), GOTEL (Grupo Oncológico para el Tratamiento y Estudio de los Linfomas).
    Haematologica; 2007 Nov 15; 92(11):1489-94. PubMed ID: 18024397
    [Abstract] [Full Text] [Related]

  • 5. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
    Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA.
    Cancer; 2005 Oct 15; 104(8):1661-7. PubMed ID: 16149091
    [Abstract] [Full Text] [Related]

  • 6. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
    Hainsworth JD, Litchy S, Morrissey LH, Andrews MB, Grimaldi M, McCarty M, Greco FA.
    J Clin Oncol; 2005 Mar 01; 23(7):1500-6. PubMed ID: 15632411
    [Abstract] [Full Text] [Related]

  • 7. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
    Zimmermann H, Reinke P, Neuhaus R, Lehmkuhl H, Oertel S, Atta J, Planker M, Gärtner B, Lenze D, Anagnostopoulos I, Riess H, Trappe RU.
    Cancer; 2012 Oct 01; 118(19):4715-24. PubMed ID: 22392525
    [Abstract] [Full Text] [Related]

  • 8. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
    Micallef IN, Kahl BS, Maurer MJ, Dogan A, Ansell SM, Colgan JP, Geyer S, Inwards DJ, White WL, Habermann TM.
    Cancer; 2006 Dec 15; 107(12):2826-32. PubMed ID: 17099879
    [Abstract] [Full Text] [Related]

  • 9. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW.
    J Clin Oncol; 2009 Jul 10; 27(20):3354-62. PubMed ID: 19451438
    [Abstract] [Full Text] [Related]

  • 10. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
    Oertel S, Trappe RU, Zeidler K, Babel N, Reinke P, Hummel M, Jonas S, Papp-Vary M, Subklewe M, Dörken B, Riess H, Gärtner B.
    Ann Hematol; 2006 Jul 10; 85(7):478-84. PubMed ID: 16586109
    [Abstract] [Full Text] [Related]

  • 11. Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen.
    Fohrer C, Caillard S, Koumarianou A, Ellero B, Woehl-Jaeglé ML, Meyer C, Epailly E, Chenard MP, Lioure B, Natarajan-Ame S, Maloisel F, Lutun P, Kessler R, Moulin B, Bergerat JP, Wolf P, Herbrecht R.
    Br J Haematol; 2006 Sep 10; 134(6):602-12. PubMed ID: 16889621
    [Abstract] [Full Text] [Related]

  • 12. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
    Knoop C, Kentos A, Remmelink M, Garbar C, Goldman S, Feremans W, Estenne M.
    Clin Transplant; 2006 Sep 10; 20(2):179-87. PubMed ID: 16640524
    [Abstract] [Full Text] [Related]

  • 13. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution.
    Choquet S, Oertel S, LeBlond V, Riess H, Varoqueaux N, Dörken B, Trappe R.
    Ann Hematol; 2007 Aug 10; 86(8):599-607. PubMed ID: 17522862
    [Abstract] [Full Text] [Related]

  • 14. A new schedule of CHOP/rituximab plus granulocyte-macrophage colony-stimulating factor is an effective rescue for patients with aggressive lymphoma failing autologous stem cell transplantation.
    Olivieri A, Lucesole M, Capelli D, Gini G, Montanari M, Candela M, Troiani E, Scortechini I, Poloni A, Leoni P.
    Biol Blood Marrow Transplant; 2005 Aug 10; 11(8):627-36. PubMed ID: 16041313
    [Abstract] [Full Text] [Related]

  • 15. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.
    Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R.
    Semin Oncol; 2003 Apr 10; 30(2):243-7. PubMed ID: 12720145
    [Abstract] [Full Text] [Related]

  • 16. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines.
    Rigacci L, Mappa S, Nassi L, Alterini R, Carrai V, Bernardi F, Bosi A.
    Hematol Oncol; 2007 Dec 10; 25(4):198-203. PubMed ID: 17654614
    [Abstract] [Full Text] [Related]

  • 17. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr 10; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 18. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
    Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S, German PTLD Study Group, European PTLD Network.
    Lancet Oncol; 2012 Feb 10; 13(2):196-206. PubMed ID: 22173060
    [Abstract] [Full Text] [Related]

  • 19. CD20 expression predicts survival in paediatric post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation.
    Orjuela MA, Alobeid B, Liu X, Siebert AL, Kott ER, Addonizio LJ, Morris E, Garvin JH, Lobritto SJ, Cairo MS.
    Br J Haematol; 2011 Mar 10; 152(6):733-42. PubMed ID: 21275950
    [Abstract] [Full Text] [Related]

  • 20. Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.
    Trappe RU, Choquet S, Reinke P, Dreyling M, Mergenthaler HG, Jäger U, Kebelmann-Betzing C, Jonas S, Lehmkuhl H, Anagnostopoulos I, Leblond V, Hetzer R, Dörken B, Riess H, Oertel S.
    Transplantation; 2007 Dec 27; 84(12):1708-12. PubMed ID: 18165786
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.